Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15016057 | 0.84 | — | — | |
| SCHEMBL2066472 | 0.84 | — | — | |
| SCHEMBL1659872 | 0.81 | MCHR1 (0.36) | — | |
| SCHEMBL4275431 | 0.80 | — | — | |
| SCHEMBL1002795 | 0.79 | TRPV4 (0.35) | — | |
| SCHEMBL303339 | 0.76 | — | — | |
| SCHEMBL9481529 | 0.75 | ADRA2A (0.35) | KMT2AADRA2AADRA2BADRA2C | |
| SCHEMBL2066891 | 0.75 | — | — | |
| SCHEMBL1494104 | 0.75 | TLR8 (0.37) | TLR8MEN1POLBKMT2A | |
| SCHEMBL2066668 | 0.73 | HTT (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331715-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | claimed |
| CN-116406362-A | Spiro [3.3] heptane derivatives for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-07-07 | — | — | CN | claimed |
| CN-114206886-A | Luminescent gold (III) compound, method for preparing same, and organic light emitting device using same | 广东聚华印刷显示技术有限公司 | 2022-03-18 | — | — | CN | claimed |
| US-10934304-B2 | Spirocyclic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2021-03-02 | — | — | US | claimed |
| WO-2021016814-A1 | LUMINESCENT GOLD (III) COMPOUND, METHOD FOR PREPARING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | GUANGDONG JUHUA PRINTED DISPLAY TECHNOLOGY CO., LTD. (CN) | 2021-02-04 | — | — | WO | claimed |
| EP-3107898-B1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-01-06 | — | — | EP | claimed |
| US-20200207776-A1 | SPIROCYCLIC COMPOUNDS | Zeno Royalties & Milestones, LLC | 2020-07-02 | — | — | US | claimed |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-23 | — | — | US | claimed |
| EP-3523306-A1 | SPIROCYCLIC COMPOUNDS | Zeno Royalties & Milestones, LLC (US) | 2019-08-14 | — | — | EP | claimed |
| US-20180282309-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | US | claimed |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-03 | — | — | US | claimed |
| WO-2018067512-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | WO | claimed |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | claimed |
| EP-3107898-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2016-12-28 | — | — | EP | claimed |
| US-9156829-B2 | Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-13 | — | — | US | claimed |
| WO-2015124932-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-08-27 | — | — | WO | claimed |
| US-20150232460-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | US | claimed |
| EP-2307024-B1 | SUBSTITUTED CARBAMATE DERIVATIVES AS MODULATORS OF CORTICOTROPIN-RELEASING FACTOR RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-01-09 | — | — | EP | claimed |
| EP-0586393-B1 | SUBSTITUTED-2-PHENYL-3-METHOXYPROPENOATES AS FUNGICIDES | ZENECA LTD (GB) | 1998-06-17 | — | — | EP | claimed |
| US-20230331715-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11739070-B2 | C5A receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2023-08-29 | — | — | US | disclosed |
| CN-110769821-B | Spiro indolines as IL-17 modulators | UCB生物制药有限责任公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116406362-A | Spiro [3.3] heptane derivatives for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-07-07 | — | — | CN | disclosed |
| US-11685729-B2 | C5a receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2023-06-27 | — | — | US | disclosed |
| EP-4116303-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | Loxo Oncology, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| CN-114206886-A | Luminescent gold (III) compound, method for preparing same, and organic light emitting device using same | 广东聚华印刷显示技术有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-107690434-B | Fused tricyclic imidazopyrazine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20210122736-A1 | C5A RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD. (CH) | 2021-04-29 | — | — | US | disclosed |
| US-20210115058-A1 | SPIROCYCLIC COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2021-04-22 | — | — | US | disclosed |
| US-10934304-B2 | Spirocyclic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2021-03-02 | — | — | US | disclosed |
| WO-2021016814-A1 | LUMINESCENT GOLD (III) COMPOUND, METHOD FOR PREPARING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME | GUANGDONG JUHUA PRINTED DISPLAY TECHNOLOGY CO., LTD. (CN) | 2021-02-04 | — | — | WO | disclosed |
| EP-3107898-B1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-01-06 | — | — | EP | disclosed |
| EP-3740477-A1 | C5A RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-25 | — | — | EP | disclosed |
| EP-3740476-A1 | C5A RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-25 | — | — | EP | disclosed |
| US-20200347029-A1 | C5A RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-11-05 | — | — | US | disclosed |
| CN-111683937-A | C5a receptor modulators | 爱杜西亚药品有限公司 | 2020-09-18 | — | — | CN | disclosed |
| CN-111615513-A | C5a receptor modulators | 爱杜西亚药品有限公司 | 2020-09-01 | — | — | CN | disclosed |
| CN-105829307-B | Tetrahydroimidazopyridine derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2020-07-24 | — | — | CN | disclosed |
| US-20200207776-A1 | SPIROCYCLIC COMPOUNDS | Zeno Royalties & Milestones, LLC | 2020-07-02 | — | — | US | disclosed |
| EP-3080128-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3080127-B1 | IMIDAZOPYRIMIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-24 | — | — | EP | disclosed |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-23 | — | — | US | disclosed |
| EP-3080123-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-17 | — | — | EP | disclosed |
| EP-3080129-B1 | IMIDAZOTRIAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-03 | — | — | EP | disclosed |
| EP-3080130-B1 | TRIAZOLOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-03 | — | — | EP | disclosed |
| EP-3080112-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-03 | — | — | EP | disclosed |
| EP-3080111-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-05-27 | — | — | EP | disclosed |
| EP-3303337-B1 | FUSED TRICYCLIC IMIDAZO PYRAZINES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-05-27 | — | — | EP | disclosed |
| US-10611766-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY INC. (US) | 2020-04-07 | — | — | US | disclosed |
| EP-3080118-B1 | TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-03-04 | — | — | EP | disclosed |
| US-10472362-B2 | Fused tricyclic imidazo pyrazines as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2019-11-12 | — | — | US | disclosed |
| EP-3080114-B1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-10-02 | — | — | EP | disclosed |
| EP-3080113-B1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-09-18 | — | — | EP | disclosed |
| EP-3080121-B1 | FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-09-04 | — | — | EP | disclosed |
| US-10399989-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10399990-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | LOXO ONCOLOGY, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| EP-3080126-B1 | PURINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-08-28 | — | — | EP | disclosed |
| EP-3080091-B1 | TETRAHYDROBENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-08-21 | — | — | EP | disclosed |
| EP-3523306-A1 | SPIROCYCLIC COMPOUNDS | Zeno Royalties & Milestones, LLC (US) | 2019-08-14 | — | — | EP | disclosed |
| EP-3080085-B1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-08-14 | — | — | EP | disclosed |
| WO-2019141803-A1 | C5A RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019141808-A1 | C5A RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-07-25 | — | — | WO | disclosed |
| EP-3080133-B1 | IMIDAZOTHIAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-07-10 | — | — | EP | disclosed |
| EP-3080110-B1 | TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-07-10 | — | — | EP | disclosed |
| EP-3080120-B1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-06-19 | — | — | EP | disclosed |
| EP-3080109-B1 | TRIAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-05-15 | — | — | EP | disclosed |
| EP-3080116-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-05-08 | — | — | EP | disclosed |
| EP-3080115-B1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-05-08 | — | — | EP | disclosed |
| US-10273247-B2 | Imidazothiazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2019-04-30 | — | — | US | disclosed |
| US-20180362533-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | REDX PHARMA PLC. (GB) | 2018-12-20 | — | — | US | disclosed |
| US-20180362537-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | REDX PHARMA PLC (GB) | 2018-12-20 | — | — | US | disclosed |
| US-20180298006-A1 | Fused Tricyclic Imidazo Pyrazines as Modulators of TNF Activity | UCB S.A. (BE) | 2018-10-18 | — | — | US | disclosed |
| US-20180298008-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | REDX PHARMA PLC (GB) | 2018-10-18 | — | — | US | disclosed |
| US-10093652-B2 | Tetrahydrobenzimidazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-10-09 | — | — | US | disclosed |
| US-20180282309-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | US | disclosed |
| US-10087179-B2 | Fused tricyclic imidazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-10-02 | — | — | US | disclosed |
| EP-2872508-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2018-08-29 | — | — | EP | disclosed |
| US-10053464-B2 | Triazolopyridazine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-08-21 | — | — | US | disclosed |
| US-20180222868-A1 | Indazole Derivatives as Modulators of TNF Activity | UCB PHARMA S.A. (BE) | 2018-08-09 | — | — | US | disclosed |
| EP-3350184-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | Loxo Oncology Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-03 | — | — | US | disclosed |
| US-10004737-B2 | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BY) | 2018-06-26 | — | — | US | disclosed |
| US-9988383-B2 | Purine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-06-05 | — | — | US | disclosed |
| US-9969728-B2 | Tetrahydroimidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-05-15 | — | — | US | disclosed |
| US-9969729-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-05-15 | — | — | US | disclosed |
| US-9957255-B2 | Benzotriazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-05-01 | — | — | US | disclosed |
| WO-2018067512-A1 | SPIROCYCLIC COMPOUNDS | KALYRA PHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| EP-3303337-A1 | FUSED TRICYCLIC IMIDAZO PYRAZINES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2018-04-11 | — | — | EP | disclosed |
| US-9932334-B2 | Tetrahydroimidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-04-03 | — | — | US | disclosed |
| US-9932343-B2 | Fused tricyclic benzimidazoles derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-04-03 | — | — | US | disclosed |
| US-9932342-B2 | Imidazopyrimidine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-04-03 | — | — | US | disclosed |
| US-9926313-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-03-27 | — | — | US | disclosed |
| US-9920052-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-03-20 | — | — | US | disclosed |
| US-9902720-B2 | Pyrazolopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-02-27 | — | — | US | disclosed |
| US-9890174-B2 | Fused Tricyclic imidazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-02-13 | — | — | US | disclosed |
| US-9873703-B2 | Imidazopyridazine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-01-23 | — | — | US | disclosed |
| US-9868749-B2 | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-01-16 | — | — | US | disclosed |
| US-9850240-B2 | Triazolopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2017-12-26 | — | — | US | disclosed |
| US-9815797-B2 | Fused bicyclic heteroaromatic derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2017-11-14 | — | — | US | disclosed |
| US-9790220-B2 | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-17 | — | — | US | disclosed |
| US-9714251-B2 | Imidazotriazine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2017-07-25 | — | — | US | disclosed |
| US-20170158688-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2017-06-08 | — | — | US | disclosed |
| US-20170129883-A1 | Tetrahydroimidazopyridine Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2017-05-11 | — | — | US | disclosed |
| US-20170129894-A1 | Triazolopyridazine Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2017-05-11 | — | — | US | disclosed |
| US-20170128445-A1 | Fused Imidazole and Pyrazole Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2017-05-11 | — | — | US | disclosed |
| WO-2017046604-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | REDX PHARMA PLC (GB) | 2017-03-23 | — | — | WO | disclosed |
| US-20170081321-A1 | Pyrazolopyridine Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2017-03-23 | — | — | US | disclosed |
| US-20170073340-A1 | SUBSTITUTED CYCLOPENTANES, TETRAHYDROFURANES AND PYRROLIDINES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9550737-B2 | TNF -α modulating benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2017-01-24 | — | — | US | disclosed |
| US-20160376268-A1 | Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity | SANOFI (FR) | 2016-12-29 | — | — | US | disclosed |
| US-20160376275-A1 | Imidazopyridazine Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-12-29 | — | — | US | disclosed |
| US-20160376290-A1 | Imidazothiazole Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-12-29 | — | — | US | disclosed |
| US-20160376276-A1 | Imidazotriazine Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-12-29 | — | — | US | disclosed |
| EP-3107907-A1 | SUBSTITUTED CYCLOPENTANES, TETRAHYDROFURANES AND PYRROLIDINES AS OREXIN RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2016-12-28 | — | — | EP | disclosed |
| EP-3107898-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2016-12-28 | — | — | EP | disclosed |
| WO-2016198398-A1 | FUSED TRICYCLIC IMIDAZO PYRAZINES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2016-12-15 | — | — | WO | disclosed |
| US-9475820-B2 | Substituted imidazo[1,2-a]pyrazines as TNF activity modulators | UCB BIOPHARMA SPRL (BE) | 2016-10-25 | — | — | US | disclosed |
| US-20160304512-A1 | Triazolopyridine Derivatives As Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-10-20 | — | — | US | disclosed |
| US-20160304511-A1 | Imidazopyridine Derivatives As Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-10-20 | — | — | US | disclosed |
| US-20160304513-A1 | Imidazopyridine Derivatives As Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-10-20 | — | — | US | disclosed |
| US-20160304523-A1 | Fused Tricyclic Benzimidazoles Derivatives As Modulators of TNF Activity | SANOFI (FR) | 2016-10-20 | — | — | US | disclosed |
| US-20160304470-A1 | Fused Bicyclic Heteroaromatic Derivatives As Modulators of TNF Activity | EVOTEC AG (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20160304530-A1 | Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity | UCB PHARMA S.A. (BE) | 2016-10-20 | — | — | US | disclosed |
| EP-3080121-A1 | FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080120-A1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080114-A1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080133-A1 | IMIDAZOTHIAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080118-A1 | TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080130-A1 | TRIAZOLOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080129-A1 | IMIDAZOTRIAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080126-A1 | PURINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080111-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080110-A1 | TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080107-A1 | BENZOTRIAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080116-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080109-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080123-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080091-A1 | TETRAHYDROBENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080128-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080112-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080113-A1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| EP-3080127-A1 | IMIDAZOPYRIMIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| US-20160297818-A1 | Purine Derivatives As Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-10-13 | — | — | US | disclosed |
| US-20160297837-A1 | Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity | EVOTEC (UK) LTD. (GB) | 2016-10-13 | — | — | US | disclosed |
| US-20160297799-A1 | Benzotriazole Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-10-13 | — | — | US | disclosed |
| US-20160297827-A1 | Imidazopyrimidine Derivatives As Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-10-13 | — | — | US | disclosed |
| US-20160297795-A1 | Tetrahydrobenzimidazole Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-10-13 | — | — | US | disclosed |
| US-20160289228-A1 | Tetrahydroimidazopyridine Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2016-10-06 | — | — | US | disclosed |
| US-9309243-B2 | Imidazopyridine derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2016-04-12 | — | — | US | disclosed |
| US-9156829-B2 | Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-13 | — | — | US | disclosed |
| WO-2015124934-A1 | SUBSITUTED CYCLOPENTANES, TETRAHYDROFURANES AND PYRROLIDINES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-08-27 | — | — | WO | disclosed |
| WO-2015124932-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-08-27 | — | — | WO | disclosed |
| US-20150232460-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | US | disclosed |
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | UCB Biopharma SPRL a corporation | 2015-07-23 | — | — | US | disclosed |
| US-20150191482-A1 | Imidazopyrazine Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2015-07-09 | — | — | US | disclosed |
| WO-2015086498-A1 | TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086507-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086525-A1 | FUSED TRICYCLIC BENZIMIDAZOLES DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086526-A1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086508-A1 | BENZOTRIAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086502-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086496-A1 | TRIAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086512-A1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086520-A1 | TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086509-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086505-A1 | PURINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086513-A1 | TETRAHYDROBENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086504-A1 | IMIDAZOTHIAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086527-A1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086519-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086511-A1 | TRIAZOLOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086499-A1 | IMIDAZOPYRIMIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086501-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015086503-A1 | IMIDAZOTRIAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2015-06-04 | — | — | US | disclosed |
| US-9048442-B2 | Composition containing a metal complex and organic compound, and light-emitting element using said compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-06-02 | — | — | US | disclosed |
| EP-2872511-A1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| EP-2305772-B1 | COMPOSITION CONTAINING A METAL COMPLEX AND ORGANIC COMPOUND, AND LIGHT EMITTING ELEMENT USING SAID COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-05-20 | — | — | EP | disclosed |
| EP-2872508-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2015-05-20 | — | — | EP | disclosed |
| EP-2858983-A1 | TNF -ALPHA MODULATING BENZIMIDAZOLES | UCB Biopharma SPRL (BE) | 2015-04-15 | — | — | EP | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| WO-2014009295-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014009296-A1 | IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB PHARMA S.A. (BE) | 2014-01-16 | — | — | WO | disclosed |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| WO-2013186229-A1 | TNF -ALPHA MODULATING BENZIMIDAZOLES | UCB PHARMA S.A. (BE) | 2013-12-19 | — | — | WO | disclosed |
| US-8592544-B2 | Polymeric compound containing metal complex residue and element comprising same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| US-8476294-B2 | 1H-imidazo[4,5-c]quinolinone derivatives | NOVARTIS AG (CH) | 2013-07-02 | — | — | US | disclosed |
| EP-2588456-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | Syngenta Participations AG (CH) | 2013-05-08 | — | — | EP | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| EP-2438064-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| EP-2438063-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| WO-2012001040-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
| US-20110124808-A1 | POLYMERIC COMPOUND CONTAINING METAL COMPLEX RESIDUE AND ELEMENT COMPRISING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110114890-A1 | COMPOSITION CONTAINING A METAL COMPLEX AND ORGANIC COMPOUND, AND LIGHT-EMITTING ELEMENT USING SAID COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2305772-A1 | COMPOSITION CONTAINING A METAL COMPLEX AND ORGANIC COMPOUND, AND LIGHT EMITTING ELEMENT USING SAID COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2011-04-06 | — | — | EP | disclosed |
| EP-2298828-A1 | POLYMERIC COMPOUND CONTAINING METAL COMPLEX RESIDUE AND ELEMENT COMPRISING SAME | Sumitomo Chemical Company, Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | disclosed |
| WO-2010139731-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| EP-0586393-B1 | SUBSTITUTED-2-PHENYL-3-METHOXYPROPENOATES AS FUNGICIDES | ZENECA LTD (GB) | 1998-06-17 | — | — | EP | disclosed |
| EP-0586393-B1 | SUBSTITUTED-2-PHENYL-3-METHOXYPROPENOATES AS FUNGICIDES | ZENECA LTD (GB) | 1998-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203486-A1 | Imidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | TLR8 557/4885MEN1 3644/4885POLB 2176/4885 |
| US-20160376275-A1 | Imidazopyridazine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | TLR8 414/4885MEN1 3518/4885POLB 1462/4885 |
| US-20180282309-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | TLR8 3385/4885MEN1 1294/4885POLB 4749/4885 |
| US-20210115058-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | TLR8 3962/4885MEN1 840/4885POLB 1927/4885 |
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | TNF, TNFRSF1A, NFKBIA | TLR8 859/4885MEN1 3836/4885POLB 1905/4885 |
| US-20200347029-A1 | C5A RECEPTOR MODULATORS | C5AR1, C3AR1, C5AR2 | TLR8 736/4885MEN1 1389/4885POLB 4790/4885 |
| US-10053464-B2 | Triazolopyridazine derivatives as modulators of TNF activity | TNF, TNFRSF1A, NFKBIA | TLR8 323/4885MEN1 4207/4885POLB 1521/4885 |
| US-20180298006-A1 | Fused Tricyclic Imidazo Pyrazines as Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | TLR8 212/4885MEN1 4123/4885POLB 1817/4885 |
| US-20160304523-A1 | Fused Tricyclic Benzimidazoles Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | TLR8 280/4885MEN1 4558/4885POLB 1132/4885 |
| US-20170073340-A1 | SUBSTITUTED CYCLOPENTANES, TETRAHYDROFURANES AND PYRROLIDINES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | TLR8 3746/4885MEN1 1393/4885POLB 4735/4885 |
| US-20170129894-A1 | Triazolopyridazine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | TLR8 323/4885MEN1 4207/4885POLB 1521/4885 |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | PRKCA, ABL1, MYLK2 | TLR8 1218/4885MEN1 2864/4885POLB 4212/4885 |
| US-20170129883-A1 | Tetrahydroimidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | TLR8 132/4885MEN1 3773/4885POLB 3309/4885 |
| US-20160304470-A1 | Fused Bicyclic Heteroaromatic Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | TLR8 126/4885MEN1 4252/4885POLB 2505/4885 |
| US-10611766-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | BTK, SYK, LCK | TLR8 1902/4885MEN1 3339/4885POLB 2946/4885 |
| US-20170081321-A1 | Pyrazolopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | TLR8 438/4885MEN1 3966/4885POLB 2691/4885 |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | MSR1, C3AR1, CD209 | TLR8 274/4885MEN1 1521/4885POLB 2896/4885 |
| US-20160304511-A1 | Imidazopyridine Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | TLR8 510/4885MEN1 3562/4885POLB 1862/4885 |
| US-20210122736-A1 | C5A RECEPTOR MODULATORS | C5AR1, C3AR1, C5AR2 | TLR8 747/4885MEN1 1357/4885POLB 4770/4885 |
| US-20160297827-A1 | Imidazopyrimidine Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | TLR8 393/4885MEN1 4190/4885POLB 1109/4885 |
| US-20160376290-A1 | Imidazothiazole Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | TLR8 114/4885MEN1 3370/4885POLB 3384/4885 |
| US-20160297818-A1 | Purine Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, PNP | TLR8 172/4885MEN1 4197/4885POLB 666/4885 |
| US-20160289228-A1 | Tetrahydroimidazopyridine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | TLR8 139/4885MEN1 3450/4885POLB 2755/4885 |
| US-10399990-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | BTK, SYK, LCK | TLR8 1902/4885MEN1 3339/4885POLB 2946/4885 |
| US-10004737-B2 | Fused imidazole and pyrazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, TNFRSF9 | TLR8 290/4885MEN1 3445/4885POLB 3161/4885 |
| US-20160304513-A1 | Imidazopyridine Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | TLR8 556/4885MEN1 3870/4885POLB 1695/4885 |
| US-20230331715-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, NR1I3, NR1H4 | TLR8 322/4885MEN1 1580/4885POLB 1692/4885 |
| US-20180222868-A1 | Indazole Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | TLR8 409/4885MEN1 3886/4885POLB 2946/4885 |
| US-20160376268-A1 | Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | TLR8 94/4885MEN1 3535/4885POLB 3288/4885 |
| US-20110124808-A1 | POLYMERIC COMPOUND CONTAINING METAL COMPLEX RESIDUE AND ELEMENT COMPRISING SAME | ZRANB2, ZKSCAN2, SLC39A3 | TLR8 2477/4885MEN1 783/4885POLB 1980/4885 |
| US-20160376276-A1 | Imidazotriazine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, IL1A | TLR8 610/4885MEN1 2920/4885POLB 2272/4885 |
| US-20170128445-A1 | Fused Imidazole and Pyrazole Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | TLR8 293/4885MEN1 3409/4885POLB 3193/4885 |
| US-10087179-B2 | Fused tricyclic imidazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, NFKBIA | TLR8 94/4885MEN1 3535/4885POLB 3288/4885 |
| US-11685729-B2 | C5a receptor modulators | C5AR1, C3AR1, C5AR2 | TLR8 747/4885MEN1 1357/4885POLB 4770/4885 |
| US-10399989-B2 | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer | BTK, SYK, LCK | TLR8 1902/4885MEN1 3339/4885POLB 2946/4885 |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | TLR8 3573/4885MEN1 1052/4885POLB 4758/4885 |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | MSR1, DDT, MPO | TLR8 49/4885MEN1 1975/4885POLB 1449/4885 |
| US-20160297837-A1 | Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | TLR8 272/4885MEN1 3434/4885POLB 3375/4885 |
| US-20150191482-A1 | Imidazopyrazine Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, NFKBIA | TLR8 370/4885MEN1 3891/4885POLB 3296/4885 |
| US-20180362537-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | BTK, SYK, LCK | TLR8 1902/4885MEN1 3339/4885POLB 2946/4885 |
| US-10472362-B2 | Fused tricyclic imidazo pyrazines as modulators of TNF activity | TNF, TNFRSF1A, TNFRSF9 | TLR8 233/4885MEN1 4096/4885POLB 1860/4885 |
| US-20180298008-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | BTK, SYK, LCK | TLR8 1902/4885MEN1 3339/4885POLB 2946/4885 |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | TLR8 1072/4885MEN1 3285/4885POLB 4228/4885 |
| US-10093652-B2 | Tetrahydrobenzimidazole derivatives as modulators of TNF activity | TNF, NFKBIA, TNFRSF1A | TLR8 139/4885MEN1 3871/4885POLB 1348/4885 |
| US-20140005163-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | TLR8 1072/4885MEN1 3285/4885POLB 4228/4885 |
| US-20180362533-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | BTK, SYK, LCK | TLR8 1902/4885MEN1 3339/4885POLB 2946/4885 |
| US-10273247-B2 | Imidazothiazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, TNFRSF9 | TLR8 114/4885MEN1 3370/4885POLB 3384/4885 |
| US-11739070-B2 | C5A receptor modulators | C5AR1, C3AR1, C5AR2 | TLR8 736/4885MEN1 1389/4885POLB 4790/4885 |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | TLR8 3573/4885MEN1 1052/4885POLB 4758/4885 |
| US-20200207776-A1 | SPIROCYCLIC COMPOUNDS | PKD1, AR, PKD2 | TLR8 3962/4885MEN1 840/4885POLB 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.